CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
This category includes pain that can pop up due to injuries, following surgeries, or as a symptom of an illness. What makes Journavx different is its unique way of working; instead of acting on the ...
Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.